Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
October 23, 2024
EDCC 2024 Poster
Share
- Sequencing based liquid biopsy diagnostics have primarily been focused on circulating tumor DNA (ctDNA).
- Many cancers such as breast cancer have been shown to have minimal ctDNA concentrations making these approaches less effective.
- Circulating tumor RNA (ctRNA) have gained recent interest for early cancer detection.
- CtRNA methods primarily use short read technologies limiting biological resolution by missing important full-length RNA sequence information.
- Long-read RNA sequencing provides biological information such as protein isoforms and long noncoding RNA which can improve cancer detection.
- However, detecting low abundance full length ctRNA has proved to be a major challenge limiting progress in this field.
- Wobble Genomics have integrated long-read RNA sequencing with our proprietary biochemistry method for abundance normalization (Level-Up) to enable the detection of low abundance full-length ctRNA.
- In this study, Wobble Genomics demonstrate the use of this new technology to create whole transcriptome isoform level profiles from breast cancer patients and controls to provide greater early detection potential as well as biological and clinical insights in breast cancer.
Our latest data demonstrates a limit of detection more than an order of magnitude better than the current industry benchmark, while maintaining 100% molecular specificity at that level of sensitivity
This research demonstrates the potential of liquid biopsy to enable more precise, non-invasive treatment selection, helping match patients to the most effective therapies while reducing reliance on invasive tissue biopsies.
This poster highlights Wobble Genomics’ long-read RNA sequencing platform for precise profiling of HER2 expression in breast cancer. By capturing full-length RNA transcripts, the approach enables isoform-level resolution, revealing detailed expression patterns that correlate strongly with standard IHC classifications in tumour tissue. Importantly, the study also demonstrates the potential to assess HER2 status non-invasively from blood samples, addressing a key unmet clinical need. The results show improved diagnostic accuracy and deeper insight into transcript diversity, supporting more informed patient stratification and treatment selection for HER2-targeted therapies.
This poster presents the development and analytical validation of a novel long-read RNA sequencing platform designed to detect low-abundance cancer transcripts directly from whole blood. By overcoming key limitations of traditional short-read approaches, the technology enables sensitive, full-length profiling of both short and long RNA species, even within complex biological backgrounds. The study demonstrates strong performance in detection sensitivity, precision, and transcript coverage, while also highlighting the platform’s ability to uncover clinically relevant isoforms in important cancer genes such as HER2 and TROP2. Collectively, these advances position the platform as a powerful tool for liquid biopsy applications, supporting improved cancer diagnostics, treatment monitoring, and precision medicine development.
